Monitor the company's progress in scaling production and its ability to secure new supply agreements, particularly in Israel. The stock's performance will be highly sensitive to regulatory developments in the U.S., so track any news related to FDA approvals or DEA rescheduling of psychedelic substances.
Executive Summary
Optimi Health Corp., a Canadian GMP-compliant manufacturer of psychedelic pharmaceuticals (MDMA and psilocybin), is conducting an initial public offering (IPO) of 2.5 million common shares in the U.S. The company holds key licenses (DEL, DL) that allow it to legally manufacture and supply its products to patients in Australia under the Authorised Prescribers Scheme, giving it a commercial advantage over most competitors still in the clinical phase. The IPO proceeds will be used to scale production, expand into new markets like the U.S. and Israel, and fund general operations. Despite this early-mover advantage, the company faces significant risks, including a history of substantial operating losses, a lack of profitability, and the uncertainty of future regulatory approvals, particularly in the U.S. where its products are currently classified as Schedule I substances.
Key Financial Metrics
Key Facts
- Optimi Health is a Canadian manufacturer of GMP-grade MDMA and psilocybin, holding a Drug Establishment Licence (DEL) and Dealers Licence (DL) from Health Canada.
- The company is currently generating revenue by supplying its products to patients in Australia under the Authorised Prescribers Scheme, a key competitive advantage.
- The company has a history of significant operating losses, reporting a net loss of C$3.7 million (US$2.7 million) for the fiscal year ended September 30, 2025.
- The IPO will raise approximately US$12.3 million (at the low end of the price range), with proceeds allocated to scaling production, market expansion, and working capital.
- The company's ability to enter the U.S. market is highly dependent on the future rescheduling of MDMA and psilocybin by the DEA, which is uncertain.
Financial Impact
The company reported a net loss of US$2.7 million on revenue of US$306,097 for the fiscal year ended September 30, 2025. The IPO is expected to raise approximately US$12.3 million in net proceeds.
Risk Factors
- The company has a history of significant operating losses and may not achieve profitability.
- Future revenue growth is highly dependent on uncertain regulatory approvals in key markets like the U.S.
- The company is subject to intense competition and the risk of negative public perception surrounding psychedelic drugs.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| F-1/A Filing (Primary) | 0001193125-26-121797 |
| Document: d43258dex51.htm | 0001193125-26-121797 |
| Document: d43258dex231.htm | 0001193125-26-121797 |
| Document: 0001193125-26-121797-index-headers.html | 0001193125-26-121797 |
| Document: 0001193125-26-121797-index.html | 0001193125-26-121797 |
| Document: 0001193125-26-121797.txt | 0001193125-26-121797 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | 6-K | $3.12 | awaiting T+5 | — | $3.12 (−0.00%) |
Oct 20, 2026 7d ago | 6-K | $3.36 $3.04 | ▼ −9.52% | ▼ −9.60% | $3.12 (−7.14%) |
Oct 7, 2026 20d ago | 6-K | $4.04 $3.17 | ▼ −21.66% | ▼ −20.68% | $3.12 (−22.77%) |
Oct 5, 2026 22d ago | SC 13G/A | $4.13 $3.50 | ▼ −15.25% | ▼ −15.12% | $3.12 (−24.46%) |
Sep 29, 2026 28d ago | 6-K | $4.78 $4.13 | ▼ −13.60% | ▼ −15.55% | $3.12 (−34.73%) |
Sep 23, 2026 4w ago | 6-K | $4.96 $4.71 | ▼ −5.04% | ▼ −4.37% | $3.12 (−37.10%) |
Sep 22, 2026 5w ago | 6-K | $4.96 $4.78 | ▼ −3.63% | ▼ −2.44% | $3.12 (−37.10%) |
Sep 16, 2026 5w ago | 6-K | $4.90 $4.96 | ▲ +1.22% | ▼ −0.60% | $3.12 (−36.33%) |
Sep 10, 2026 6w ago | 6-K | $4.50 $4.96 | ▲ +10.22% | ▲ +10.72% | $3.12 (−30.67%) |
Aug 26, 2026 8w ago | 6-K | $4.89 $4.70 | ▲ +3.89% | ▲ +4.15% | $3.12 (+36.20%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers